Form 4: C4 Therapeutics Executive Stewart Fisher Adjusts Stock Option Holdings Following Repricing

Stewart Fisher, Chief Scientific Officer of C4 Therapeutics, adjusts stock option holdings due to an option repricing approved by the company's Compensation Committee.

Summary

• On March 8, 2024, a Form 4 filing was submitted to the SEC by Stewart Fisher, Chief Scientific Officer of C4 Therapeutics, Inc.
• The filing details changes in beneficial ownership of derivative securities, specifically stock options.
• The transactions on March 7, 2024, involve the repricing of existing stock options.
• Fisher disposed of options with strike prices of $45.54 and $22.71 and acquired new options with a strike price of $19.
• The repricing was approved by the Compensation Committee of C4 Therapeutics' Board of Directors, and all other terms of the options remain unchanged.
• The options vest in equal quarterly installments, with vesting start dates in May 2021 and May 2022.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock option adjustments. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Management Comments

• The Compensation Committee of the Issuer's Board of Directors approved an option repricing.
• All of the other terms of the options remain unchanged.

Industry Context

Option repricing is a tool companies use to re-incentivize employees when the stock price has fallen significantly below the original option strike price. This helps retain talent and align employee interests with shareholders.

Comparison to Industry Standards

• Option repricing is a relatively common practice, especially in the biotech industry where stock prices can be volatile.
• Many companies, such as Amgen, Regeneron, and Vertex Pharmaceuticals, use stock options as a key component of their compensation packages.
• The specific terms of option grants, including vesting schedules and strike prices, vary widely based on company size, stage of development, and individual performance.

Stakeholder Impact

• The option repricing may have a slightly positive impact on employee morale by re-incentivizing key personnel.
• Shareholders may view the repricing as a necessary measure to retain talent, but some may see it as dilutive if the stock price does not recover.

Key Dates